New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk-Reference-Cited by-同舟云学术

New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk

Published:2018-09-22 Issue:6 Volume:37 Page:1085-1093
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Merseburger Axel,Bro Falkenberg Anne,Kornilova Olga J.

Funder

Ferring Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-018-2495-0.pdf

Reference34 articles.

1. Prostate cancer statistics [Internet]: Centers for Disease Control and Prevention, CDC (US). Updated on 23 May 2017. https://www.cdc.gov/cancer/prostate/statistics/index.htm . Accessed 19 Jan 2018

2. Key statistics for Prostate cancer [Internet]. American Cancer Society. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html . Accessed 19 Jan 2018

3. Tao ZQ, Shi AM, Wang KX, Zhang WD (2015) Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 19:805–812

4. Fu AZ, Tsai H-T, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL (2017) Mortality and androgen deprivation therapy as salvage treatment for biochemical recurrence after primary therapy for clinically localized prostate cancer. J Urol 197:1448–1454

5. Greiman AK, Keane TE (2017) Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease. Curr Urol Rep 18:41

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan;Frontiers in Cardiovascular Medicine;2023-10-19

2. Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom;Der Urologe;2021-08-17

3. Androgen deprivation therapy of prostate cancer and cardiovascular morbidity;Onkologie;2020-03-01

4. Retrospektive GKV-Versorgungsforschungsstudie über GnRH-Antagonisten/-Agonisten zur initialen Therapie des fortgeschrittenen Prostatakarzinoms – Verordnungsmuster und Krankenhauskosten in Deutschland;Aktuelle Urologie;2019-11-19

5. Androgen deprivation therapy of prostate cancer and cardiovascular morbidity;Urologie pro praxi;2019-10-10